SEC Form 4 · accession 0000899243-17-026210
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael John Tomsicek
Officer — Chief Financial Officer
Period of report
Nov 13, 2017
Accepted (ET)
Nov 14, 2017 · 5:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $17.75 | Nov 13, 2017 | A | 180,000 | A | — | Nov 21, 2027 | Common Shares | 180,000 | 180,000 | D |
Explanation of responses
- F1This option was granted on November 13, 2017, 25% of the shares shall vest on November 13, 2018 and the remaining shares shall vest in 36 equal monthly installments on the first day of each succeeding calendar month.